Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Magic RN who wrote (15954)	3/8/1999 3:40:00 PM
From: JeffA	Read Replies (1) \| Respond to of 90042

DAWG!! Just read this excerpt on VVUS. Their spokeswoman is named Nina Ferrari?! "....Vivus spokeswoman Nina Ferrari said the patent is important because it strengthens its sexual dysfunction product pipeline. The Menlo Park, Calif. company currently markets Muse, a drug that treats male impotence. Vivus is in preclinical studies for a topically applied product that uses the new patent's technology. Ferrari said Vivus expects to move to human trials "as soon as possible," but the company hasn't developed a specific time frame....." Careful with this. The ASAP statement is a warning to me. Out either today or tom morning. Waiting for price direction....